HCMSG - Hepatitis C Mentor & Support Group, Inc.
Search
  • About Us
    • Our Mission
    • Board of Directors
    • Medical Advisors
  • Resources
    • Corona Virus
    • Hep C Facts & Stats
    • Medications and Treatments >
      • Patient Assistance Programs
    • Reading
    • Links
  • Programs/Training
    • The Circle Model >
      • THE CIRCLE Registration
      • Group and Facilitator Guide
    • Hepatitis C Online Training
    • The Hepatitis C Education and Support Group Assistance Program
    • Healthcare Provider Training
  • Newsletter
  • Blog
  • Support Us
    • Holiday 2020
  • Contact Us

The Latest Hepatitis C Treatment Recommendations: Who Decides Your Future?

8/14/2014

1 Comment

 
                                                  By Lucinda K. Porter, RN on August 13, 2014 11:08 AM | The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) released their latest guidelines regarding hepatitis C. "When and In Whom to Initiate HCV Therapy" is part of Recommendations for Testing, Managing, and Treating Hepatitis C. I am a "the glass is half-full" kind of person, and my blogs tend to be positive. Not this time. I am concerned about these recommendations. 

Let's start with the good news. AASLD and IDSA recognize the benefits of hepatitis C treatment, particularly early treatment. They state, "Because of the myriad benefits associated with successful HCV treatment, clinicians should treat HCV-infected patients with antiviral therapy with the goal of achieving an SVR, preferably early in the course of their chronic HCV infection before the development of severe liver disease and other complications...Patients who are cured of their HCV infection experience numerous health benefits...and a reduction in the rate of progression of liver fibrosis."

However, AASLD and IDSA go on to say, "Limitations of workforce and societal resources may limit the feasibility of treating all patients within a short period of time. Therefore, when such limitations exist, initiation of therapy should be prioritized first to those specific populations that will derive the most benefit or have the greatest impact on further HCV transmission. Others should be treated as resources allow."

This means that if there aren't a lot of doctors who can treat hepatitis C in your community, or if your healthcare plan budgets its resources, then certain patients may be given priority. Your state Medicaid program, insurance plan, or healthcare organization could limit access to hepatitis C treatment based on these priorities.  

The good news is that the people who made the cut are those who need help the most--hepatitis C patients with advanced disease (stage 3 fibrosis or compensated cirrhosis ). I am NOT quibbling over their right to treatment. I wish nothing stood between them and immediate help. My issue is that we prioritize hepatitis C patients at all.

Here is the list, starting with the highest:

Highest Priority



  • Hepatitis C stage 3 fibrosis or stage 4 compensated cirrhosis
  • Organ transplant patients
  • Type 2 or 3 essential mixed cryoglobulinemia (Cryoglobulinemia is  a type of vasculitis - a group of diseases that cause damage and inflammation of the blood vessels throughout the body)
  • Proteinuria, nephrotic syndrome, or membranoproliferative glomerulonephritis (Kidney disease)


High Priority



  • Stage 2 fibrosis
  • HIV-1 coinfection
  • HBV coinfection
  • Other coexistent liver disease (eg, fatty liver)
  • Debilitating fatigue
  •             Type 2 Diabetes mellitus (insulin resistant)
  •             Porphyria cutanea tarda (a skin condition)


Persons Whose Risk of HCV Transmission is High and in Whom HCV Treatment May Yield Transmission Reduction Benefits



  • Men who have sex with men (MSM) with high-risk sexual practices
  • Active injection drug users
  • Incarcerated persons
  • Persons on long-term hemodialysis


Who Is Not a Priority for Hepatitis C Treatment?

The AASLD and IDSA guidelines say that those who are expected to die within a year from a cause unrelated to hepatitis C are not good candidates for treatment. The guidelines don't specifically recommend against treating hepatitis C patients with stage 1 fibrosis, but it is implied by the fact that they aren't prioritized. In my mind that is like saying that if you have stage 1 cancer, you should wait until you have stage 2 before getting treatment. I understand "limitations of workforce and societal resources" but rather than triage patients, shouldn't we fix the system? 

I get that the sickest should be treated first. Triaging works well in ERs, wars and natural disasters. It works because trained medical people make the decisions. The problem with triaging hepatitis C patients is that the healthcare and insurance industry are also doing the triaging. When Gilead set the price of Sovaldi at $1000 a pill, the insurance/healthcare industry had to look for cost-cutting measures. I am nervous that these guidelines will give them the justification that they need in order to avoid treating those with stage 1 fibrosis.  This means that those with limited access to healthcare, i.e. the poor, may be at the bottom of the list. 

In my next blog, I will discuss some positive points in the guidelines, including recommendations for hepatitis C patients who are not waiting for treatment.

1 Comment
yepi online link
10/21/2014 05:59:38 pm

The article you have shared here very awesome. I really like and appreciated your work. I read deeply your article, the points you have mentioned in this article are useful. I must try to follow these points and also share others.

Reply

Your comment will be posted after it is approved.


Leave a Reply.

    Archives

    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013
    July 2013
    June 2013
    May 2013
    April 2013
    March 2013
    February 2013
    January 2013
    December 2012
    November 2012
    October 2012
    September 2012
    August 2012
    July 2012
    June 2012
    May 2012
    April 2012
    March 2012
    February 2012
    January 2012
    December 2011
    November 2011
    October 2011
    September 2011
    August 2011
    July 2011
    June 2011
    May 2011

    Categories

    All

    RSS Feed

Privacy Policy